Search

Your search keyword '"Blanke, Charles"' showing total 865 results
Start Over Author "Blanke, Charles"
865 results on '"Blanke, Charles"'

301. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Author

Philip, Philip A., primary, Benedetti, Jacqueline, additional, Corless, Christopher L., additional, Wong, Ralph, additional, O'Reilly, Eileen M., additional, Flynn, Patrick J., additional, Rowland, Kendrith M., additional, Atkins, James N., additional, Mirtsching, Barry C., additional, Rivkin, Saul E., additional, Khorana, Alok A., additional, Goldman, Bryan, additional, Fenoglio-Preiser, Cecilia M., additional, Abbruzzese, James L., additional, and Blanke, Charles D., additional

Published
2010
Full Text
View/download PDF

302. Pain and Emotional Well-Being Outcomes in Southwest Oncology Group–Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer

Author

Moinpour, Carol M., primary, Vaught, Nancy L., additional, Goldman, Bryan, additional, Redman, Mary W., additional, Philip, Philip A., additional, Millwood, Barbara, additional, Lippman, Scott M., additional, Seay, Thomas E., additional, Flynn, Patrick J., additional, O'Reilly, Eileen M., additional, Rowland, Kendrith M., additional, Wong, Ralph P., additional, Benedetti, Jacqueline, additional, and Blanke, Charles D., additional

Published
2010
Full Text
View/download PDF

303. S9511

Author

Blanke, Charles D., primary, Chansky, Kari, additional, Christman, Kathy L., additional, Hundahl, Scott A., additional, Issell, Brian F., additional, Van Veldhuizen, Peter J., additional, Budd, G Thomas, additional, Abbruzzese, James L., additional, and Macdonald, John S., additional

Published
2010
Full Text
View/download PDF

304. Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set

Author

de Gramont, Aimery, primary, Hubbard, Joleen, additional, Shi, Qian, additional, O'Connell, Michael J., additional, Buyse, Marc, additional, Benedetti, Jacqueline, additional, Bot, Brian, additional, O'Callaghan, Chris, additional, Yothers, Greg, additional, Goldberg, Richard M., additional, Blanke, Charles D., additional, Benson, Al, additional, Deng, Qiqi, additional, Alberts, Steven R., additional, Andre, Thierry, additional, Wolmark, Norman, additional, Grothey, Axel, additional, and Sargent, Daniel, additional

Published
2010
Full Text
View/download PDF

309. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Author

DeMatteo, Ronald P, primary, Ballman, Karla V, additional, Antonescu, Cristina R, additional, Maki, Robert G, additional, Pisters, Peter WT, additional, Demetri, George D, additional, Blackstein, Martin E, additional, Blanke, Charles D, additional, von Mehren, Margaret, additional, Brennan, Murray F, additional, Patel, Shreyaskumar, additional, McCarter, Martin D, additional, Polikoff, Jonathan A, additional, Tan, Benjamin R, additional, and Owzar, Kouros, additional

Published
2009
Full Text
View/download PDF

311. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Author

Heinrich, Michael C., primary, Owzar, Kouros, additional, Corless, Christopher L., additional, Hollis, Donna, additional, Borden, Ernest C., additional, Fletcher, Christopher D.M., additional, Ryan, Christopher W., additional, von Mehren, Margaret, additional, Blanke, Charles D., additional, Rankin, Cathryn, additional, Benjamin, Robert S., additional, Bramwell, Vivien H., additional, Demetri, George D., additional, Bertagnolli, Monica M., additional, and Fletcher, Jonathan A., additional

Published
2008
Full Text
View/download PDF

312. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

Author

Whitehead, Robert P., primary, Rankin, Cathryn, additional, Hoff, Paulo M. G., additional, Gold, Philip J., additional, Billingsley, Kevin G., additional, Chapman, Robert A., additional, Wong, Lucas, additional, Ward, John H., additional, Abbruzzese, James L., additional, and Blanke, Charles D., additional

Published
2008
Full Text
View/download PDF

313. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Author

Blanke, Charles D., primary, Demetri, George D., additional, von Mehren, Margaret, additional, Heinrich, Michael C., additional, Eisenberg, Burton, additional, Fletcher, Jonathan A., additional, Corless, Christopher L., additional, Fletcher, Christopher D.M., additional, Roberts, Peter J., additional, Heinz, Daniela, additional, Wehre, Elisabeth, additional, Nikolova, Zariana, additional, and Joensuu, Heikki, additional

Published
2008
Full Text
View/download PDF

314. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Author

Blanke, Charles D., primary, Rankin, Cathryn, additional, Demetri, George D., additional, Ryan, Christopher W., additional, von Mehren, Margaret, additional, Benjamin, Robert S., additional, Raymond, A. Kevin, additional, Bramwell, Vivien H.C., additional, Baker, Laurence H., additional, Maki, Robert G., additional, Tanaka, Michael, additional, Hecht, J. Randolph, additional, Heinrich, Michael C., additional, Fletcher, Christopher D.M., additional, Crowley, John J., additional, and Borden, Ernest C., additional

Published
2008
Full Text
View/download PDF

316. Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: A report of three new cases with mutational analysis and comparative genomic hybridization

Author

Agaimy, Abbas, primary, Pelz, Antje-Friederike, additional, Corless, Christopher, additional, Wünsch, Peter, additional, Heinrich, Michael, additional, Hofstaedter, Ferdinand, additional, Dietmaier, Wolfgang, additional, Blanke, Charles, additional, Wieacker, Peter, additional, Roessner, Albert, additional, Hartmann, Arndt, additional, and Schneider-Stock, Regine, additional

Published
2007
Full Text
View/download PDF

317. NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines

Author

Demetri, George D., primary, Benjamin, Robert S., additional, Blanke, Charles D., additional, Blay, Jean-Yves, additional, Casali, Paolo, additional, Choi, Haesun, additional, Corless, Christopher L., additional, Debiec-Rychter, Maria, additional, DeMatteo, Ronald P., additional, Ettinger, David S., additional, Fisher, George A., additional, Fletcher, Christopher D. M., additional, Gronchi, Alessandro, additional, Hohenberger, Peter, additional, Hughes, Miranda, additional, Joensuu, Heikki, additional, Judson, Ian, additional, Le Cesne, Axel, additional, Maki, Robert G., additional, Morse, Michael, additional, Pappo, Alberto S., additional, Pisters, Peter W. T., additional, Raut, Chandrajit P., additional, Reichardt, Peter, additional, Tyler, Douglas S., additional, Van den Abbeele, Annick D., additional, von Mehren, Margaret, additional, Wayne, Jeffrey D., additional, and Zalcberg, John, additional

Published
2007
Full Text
View/download PDF

319. The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer

Author

Goldberg, Richard M., primary, Rothenberg, Mace L., additional, Van Cutsem, Eric, additional, Benson, Al B., additional, Blanke, Charles D., additional, Diasio, Robert B., additional, Grothey, Axel, additional, Lenz, Heinz-Josef, additional, Meropol, Neal J., additional, Ramanathan, Ramesh K., additional, Becerra, Carlos H. Roberto, additional, Wickham, Rita, additional, Armstrong, Delma, additional, and Viele, Carol, additional

Published
2007
Full Text
View/download PDF

328. Gastrointestinal Stromal Tumors.

Author

Zalcberg, John R., Yip, Desmond, Hemmings, Christine, Mann, Bruce, and Blanke, Charles D.

Abstract

Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development of effective targeted therapies such imatinib mesylate in a relatively short period of time for both the advanced and adjuvant settings. Sunitinib, a multikinase inhibitor, has also been proven as second line therapy and other biological agents such as nilotinib and sorafenib are in clinical testing. Mutational analysis of GIST contributes predictive and prognostic information helping to guide biological therapies. The multidisciplinary management of GIST has also challenged some traditional oncological paradigms. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

330. Colaboradores

Author

Abrams, Charles S., Accurso, Frank J., Afdhal, Nezam H., Akin, Cem, Aksamit, Allen J., Jr., Al-Awqati, Qais, Allos, Ban Mishu, Altshuler, David, Aminoff, Michael J., Anderson, Jeffrey L., Anderson, Karl E., Anderson, Larry J., Antman, Karen H., Antony, Aśok C., Appel, Gerald B., Appelbaum, Frederick R., Arend, William P., Arguin, Paul, Armitage, James O., Armstrong, Cheryl A., Arnaout, M. Amin, Arnold, Robert, Atkins, David, Atkinson, William L., Ausiello, Dennis, Bacon, Bruce R., Bagby, Grover C., Bain, Barbara J., Bajorin, Dean F., Ballow, Mark, Baloh, Robert W., Barasch, Jonathan, Barbano, Richard L., Baron, Murray G., Barrett-Connor, Elizabeth, Barry, Michael J., Barshop, Bruce A., Bartlett, John G., Barton, Mary, Basner, Robert C., Baum, Stephen G., Bausch, Daniel G., Bayer, Arnold S., Bazari, Hasan, Beigel, John H., Beller, George A., Bennett, Robert M., Berger, Joseph R., Berk, Paul, Berliner, Nancy, Bernat, James L., Bierman, Philip J., Bistrian, Bruce R., Biundo, Joseph J., Blanke, Charles D., Blankson, Joel N., Blaser, Martin J., Blattner, William A., Bleck, Thomas P., Boden, William E., Boland, C. Richard, Bolognia, Jean, Bonomo, Robert, Borish, Larry, Bosque, Patrick J., Brand, Randall, Brook, Itzhak, Brunetti, Enrico, Buchner, David M., Buffet, Pierre A., Bunn, H. Franklin, Calabresi, Peter A., Calfee, David P., Calkins, Hugh, Cameron, Douglas, Camilleri, Michael, Cannon, Grant W., Cappellini, Maria Domenica, Carabello, Blase A., Carvalho, Edgar M., Castellanos, Agustin, Chalasani, Naga P., Chambers, Henry, Charlson, Mary, Cheshire, William P., Jr., Chinnery, Patrick F., Christiani, David C., Clemmons, David R., Cohen, Jeffrey, Cohen, Myron S., Cohen, Steven P., Cohn, Steven L., Colebunders, Robert, Connors, Joseph M., Cook, Deborah J., Corey, C. Ralph, Cowan, Kenneth H., Craig, William A., Croft, Simon L., Crow, Mary K., Crump, John A., Cullen, Mark R., Curhan, Gary C., Damon, Inger K., Daniels, Troy E., Davidson, Nancy, DeAngelis, Lisa M., DeCamp, Malcolm M., Del Rio, Carlos, Demetri, George D., Demling, Robert H., Deuster, Patricia A., Diasio, Robert B., Diemert, David J., Digre, Kathleen B., Douglas, John M., Jr., and Drazen, Jeffrey M.

Published
2014
Full Text
View/download PDF

331. Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment.

Author

Markman, Maurie, Saltz, Leonard B., Strother, John M., and Blanke, Charles D.

Abstract

Angiogenesis is an essential step in the growth and metastases of many solid tumors,including colorectal cancer (CRC). Efforts to inhibit angiogenesis as a potential antineoplastic strategy began more than 30 yr ago, and numerous angiogenic growth factors have subsequently been identified in large bowel tumors. The most successful antiangiogenic strategy to date has focused on inhibiting vascular endothelial growth factor (VEGF). [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

332. Current Status of Colorectal Cancer Therapy.

Author

Faigel, Douglas O., Kochman, Michael L., Strother, John, Billingsley, Kevin G., Hung, Arthur Y., and Blanke, Charles D.

Abstract

In 2004, the American Cancer Society estimated that approx 150,000 new cases of colorectal cancer would occur in the United States and that more than 57,000 Americans would die of the disease, making it the second most common cause of cancer-related death (1). Despite improvements in screening techniques, 30-40% of patients with colorectal cancer present with locoregionally advanced or metastatic disease and are not candidates for potentially curative therapy. Overall, progress in the surgical and neoadjuvant/adjuvant management of locally confined colorectal cancer has been rapid and very encouraging over the past several years. In addition, median survival in advanced disease has improved almost fourfold, as several new and active salvage systemic agents have emerged and been rapidly integrated into first-line regimens. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

337. Liste des collaborateurs

Author

Antman, Karen H., Appelbaum, Frederick R., Armitage, James O., Bajorin, Dean F., Bierman, Philip J., Blanke, Charles D., Boland, C. Richard, Brand, Randall, Connors, Joseph M., Cowan, Kenneth H., Davidson, Nancy, DeAngelis, Lisa M., Demetri, George D., Einhorn, Lawrence H., Ettinger, David S., Faigel, Douglas O., Gagel, Robert F., Gertz, Morie A., Greco, F. Anthony, Hainsworth, John D., Jemal, Ahmedin, Jensen, Robert T., Kantarjian, Hagop, Komrokji, Rami S., Lerner, Adam, List, Alan F., Lynch, Henry T., Markman, Maurie, Moscow, Jeffrey A., O'Brien, Susan, Perry, Michael C., Posner, Marshall R., Rajkumar, S. Vincent, Roberts, Lewis R., Rugo, Hope S., Rustgi, Anil K., Schuchter, Lynn M., Small, Eric J., Tempero, Margaret, and Thun, Michael J.

Published
2013
Full Text
View/download PDF

339. Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma

Author

Siegel, Abby B., El-Khoueiry, Anthony B., Finn, Richard S., Guthrie, Katherine A., Goyal, Abhishek, Venook, Alan P., Blanke, Charles D., Verna, Elizabeth C., Dove, Lorna, Emond, Jean, Kato, Tomoaki, Samstein, Benjamin, Busuttil, Ronald, Remotti, Helen, Coffey, Amy, and Brown Jr, Robert S.

Abstract

AbstractLiver transplantation offers excellent long-term survival for hepatocellular carcinoma (HCC) patients who fall within established criteria. For those outside such criteria, or with high-risk pathologic features in the explant, HCC recurrence rates are higher. We conducted a multicenter phase I trial of sorafenib in liver transplantation patients with high-risk HCC. Subjects had HCC outside the Milan criteria (pre- or post-transplant), poorly differentiated tumors, or vascular invasion. We used a standard 3+3 phase I design with a planned duration of treatment of 24 weeks. Correlative studies included the number of circulating endothelial cells (CECs), plasma biomarkers, and tumor expression of p-Erk, p-Akt, and c-Met in tissue micro-arrays. We enrolled 14 patients with a median age of 63 years. Of these, 93 were men and 71 had underlying hepatitis C virus (HCV) and 21 had HBV. The maximum tolerated dose of sorafenib was 200 mg BID. Grade 3-4 toxicities seen in >10 of subjects included leukopenia (21), elevated gamma-glutamyl transferase (21), hypertension (14), hand-foot syndrome (14) and diarrhea (14). Over a median follow-up of 953 days, one patient died and four recurred. The mean CEC number at baseline was 21 cells/4 ml for those who recurred, and 80 cells/4 ml for those who did not (p=0.10). Mean soluble vascular endothelial growth factor receptor-2 levels decreased after 1 month on sorafenib (p=0.09), but did not correlate with recurrence. There was a trend for tumor c-Met expression to correlate with increased risk of recurrence. Post-transplant sorafenib was found to be feasible and tolerable at 200 mg PO BID. The effect of post-transplant sorafenib on recurrence-free survival is potentially promising but needs further validation in a larger study.© 2015 S. Karger AG, Basel

Published
2015
Full Text
View/download PDF

341. 38: Paraneoplastic Phenomena Associated with Gastrointestinal Cancer.

Author

Blanke, Charles D. and Washington, Kay

Abstract

Describes several paraneoplastic phenomena associated with gastrointestinal (GI) neoplasms. Epidemiology and pathological features of the syndrome; Skin manifestations of the malignancy; Aggressiveness of the GI tumor.

Published
1999

344. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132.

Author

Wang, Dian, Zhang, Qiang, Blanke, Charles, Demetri, George, Heinrich, Michael, Watson, James, Hoffman, John, Okuno, Scott, Kane, John, Mehren, Margaret, and Eisenberg, Burton

Abstract

Background: Imatinib inhibits the KIT and PDGFR tyrosine kinases, resulting in its notable antitumor activity in gastrointestinal stromal tumor (GIST). We previously reported the early results of a multi-institutional prospective trial (RTOG 0132) using neoadjuvant/adjuvant imatinib either in primary resectable GIST or as a planned preoperative cytoreduction agent for metastatic/recurrent GIST. Methods.: Patients with primary GIST (≥5 cm, group A) or resectable metastatic/recurrent GIST (≥2 cm, group B) received neoadjuvant imatinib (600 mg/day) for approximately 2 months and maintenance postoperative imatinib for 2 years. We have now updated the clinical outcomes including progression-free survival, disease-specific survival, and overall survival at a median follow-up of 5.1 years, and we correlate these end points with duration of imatinib therapy. Results: Sixty-three patients were originally entered (53 analyzable: 31 in group A and 22 in group B). Estimated 5-year progression-free survival and overall survival were 57% in group A, 30% in group B; and 77% in group A, 68% in group B, respectively. Median time to progression has not been reached for group A and was 4.4 years for group B. In group A, in 7 of 11 patients, disease progressed >2 years from registration; 6 of 7 patients with progression had stopped imatinib before progression. In group B, disease progressed in 10 of 13 patients >2 years from registration; 6 of 10 patients with progressing disease had stopped imatinib before progression. There was no significant increase in toxicity compared with our previous short-term analysis. Conclusions: This long-term analysis suggests a high percentage of patients experienced disease progression after discontinuation of 2-year maintenance imatinib therapy after surgery. Consideration should be given to studying longer treatment durations in intermediate- to high-risk GIST patients. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

348. Perioperative Treatment of Gastrointestinal Stromal Tumors.

Author

dos Santos Fernandes, Gustavo, Blanke, Charles D., Freitas, Daniela, Guedes, Rodrigo, and Hoff, Paulo M.

Abstract

The article describes the multidisciplinary management of gastrointestinal stromal tumor (GIST). The discovery of the central role of KIT proto-oncogene mutations in the pathogenesis of the tumor and the development of specific inhibitors of KIT tyrosinase kinase (TK) function has changed the treatment of GIST. In fact, the adjuvant use of imatinib reduces the risk of recurrence of tumor.

Published
2009

349. SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer.

Author

Patel, Sandip P., Guadarrama, Elizabeth, Chae, Young Kwang, Dennis, Michael J., Powers, Benjamin C., Liao, Chih‐Yi, Ferri, William A., George, Thomas J., Sharon, Elad, Ryan, Christopher W., Othus, Megan, Lopez, Gabby, Blanke, Charles D., and Kurzrock, Razelle

Subjects
*IMMUNE checkpoint inhibitors, *CANCER patients, *ASPARTATE aminotransferase, *OVERALL survival, *GALLBLADDER cancer, BILIARY tract cancer
Abstract

Introduction: Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open‐label study was designed to evaluate the anticancer activity of nivolumab plus ipilimumab in patients with advanced gallbladder cancer. Methods: Nineteen patients with advanced gallbladder cancer refractory to ≥1 previous therapy received nivolumab 240 mg intravenously every 2 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks until disease progression or unacceptable toxicity. The primary end point was confirmed radiographic overall response rate (ORR) (complete response [CR] + partial response [PR] confirmed on subsequent scan); secondary end points included unconfirmed overall response, clinical benefit rate (confirmed and unconfirmed responses + stable disease >6 months), progression‐free survival, overall survival, and toxicity. Results: The confirmed ORR was 16% (CR, n = 1 [5%]; PR, n = 2 [11%]); all were microsatellite stable, and the confirmed CR had undetectable programmed death‐ligand 1 by immunohistochemistry. The unconfirmed ORR and clinical benefit rates were both 32%. The median duration of response was 14.8 months (range, 4–35.1+ months). The 6‐month progression‐free survival was 26% (95% CI, 12–55). The median overall survival was 7.0 months (95% CI, 3.9–19.1). The most common toxicities were fatigue (32%), anemia (26%), and anorexia (26%). Aspartate aminotransferase elevation was the most common grade 3/4 toxicity (11%). There was 1 possibly related death (sepsis with attendant hepatic failure). Conclusions: Ipilimumab plus nivolumab was well tolerated and showed modest efficacy with durable responses in previously treated patients with advanced gallbladder cancer. Clinical Trial Registration: NCT02834013 (ClincialTrials.gov). Plain Language Summary: This prospective study assessed the efficacy and safety of nivolumab plus ipilimumab in 19 patients with advanced gallbladder cancer refractory to previous therapy. The combination demonstrated modest efficacy with a 16% confirmed overall response rate, durable responses, and manageable toxicities, suggesting potential benefits for this challenging patient population. Ipilimumab plus nivolumab demonstrated modest efficacy with durable responses and manageable toxicity in previously treated patients with advanced gallbladder cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results